University of California, Los Angeles
ICOC Committed funds:
Awards as PI
|New Faculty II||Stem Cells for Immune System Regeneration to Fight Cancer||$3,247,000|
|Disease Team Therapy Planning I||Genetic Re-programming of Stem Cells to Fight Cancer||$110,000|
|Disease Team Therapy Development - Research||Genetic Re-programming of Stem Cells to Fight Cancer||$19,999,563|
Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.
The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy.
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.
Allelic Exclusion and Peripheral Reconstitution by TCR Transgenic T Cells Arising From Transduced Human Hematopoietic Stem/Progenitor Cells.